Espoo, Finland, March 2022 –TrueMed announced it has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. Department of Homeland Security (DHS) Science and Technology Directorate (S&T). The goal of the CRADA is to test and evaluate TrueMed’s capability for identifying illicit substances, such as fentanyl.
“This CRADA provides TrueMed with an accelerated path for demonstrating our capabilities in illicit substance detection”, says Jyrki Berg, CEO and Co-founder of TrueMed. “Our collaboration will enable a new method for detecting illicit substances in large volumes in the field, instantly and safely”.
The purpose of this CRADA is to provide a mechanism for TrueMed and DHS to obtain data on a variety of illicit opioid powders as pure forms and in mixtures, as well as precursors and common adulterants, and for DHS to evaluate the potential of the TrueMed system to address Program and Component needs.
“This CRADA enables our teams to get access to samples of illicit substances to train our artificial intelligence, while building a collaborative relationship with laboratory and law enforcement stakeholders”, says Tuomas Kannas, SVP and Co-founder of TrueMed.
TrueMed is developing an optical detection system for detecting goods in the illicit trade. Our mission is to save lives, societies, and revenues. TrueMed enables every mobile phone to be a powerful scanner for detecting illicit goods.
TrueMed was founded in 2019 and is based in Finland and Palo Alto, California, US. Read more at truemedinc.com
This publication is based upon work conducted under the U.S. Department of Homeland Security Cooperative Research and Development Agreement No. 21-MCS-031
Disclaimer. “The views and/or conclusions contained in this document are those of the author(s) and should not be interpreted as necessarily representing the official policies, either expressed or implied, of the U.S. Department of Homeland Security (DHS), and do not constitute a DHS endorsement of the equipment tested or evaluated.”